侵袭性曲霉病治疗进展  

Update of the treatment of invasive aspergillosis

作　　者：王双双 胡小平[2] 于波[2] WANG Shuangshuang;HU Xiaoping;YU Bo(Shantou University Medical College,Shantou 515041,China;Department of Dermatology,Shenzhen Hospital of Peking University,Shenzhen 518036,China)

机构地区：[1]汕头大学医学院,汕头515041 [2]北京大学深圳医院皮肤科,深圳518036

出　　处：《中国麻风皮肤病杂志》2021年第8期543-548,共6页China Journal of Leprosy and Skin Diseases

基　　金：国家自然基金面上项目(编号:81673053);深圳市三名工程项目资助(编号:SZSM201812059)。

摘　　要：侵袭性曲霉病(invasive aspergillosis,IA)是由曲霉感染引起的较为严重的深部真菌感染性疾病。近年来,随着免疫抑制剂、广谱抗菌药物的广泛使用,器官移植技术等侵入性诊疗的普遍开展,以及恶性肿瘤、获得性免疫缺陷综合征患者人数的不断增加,IA发病率呈逐年上升趋势。如何降低IA的高死亡率是临床亟待解决的难题,本文就IA的临床治疗研究进展进行综述。Invasive aspergillosis(IA)is a serious deep fungal infection caused by Aspergillus fungi.In recent years,the incidence of IA is increasing year by year with the widespread use of immunosuppressants and broad-spectrum antibiotics,the widespread development of invasive diagnosis and treatment such as organ transplantation,and the increasing number of patients with malignant tumors and acquired immunodeficiency syndrome.The high mortality rate of IA patients is still a serious threat to their lives and health.The update of the treatment of invasive aspergillosis is reviewed in this paper.

关 键 词：侵袭性曲霉病 抗真菌药物 治疗 

分 类 号：R519[医药卫生—内科学]